Kornimate/medical-research-clean huggingface dataset:
effect of virtual reality on prostaglandin levels in adolescent females with primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study will be conducted to study the effect of virtual reality therapy on prostaglandin levels in adolescent females with primary dysmenorrhea.

primary dysmenorrhea is thought to be caused by excessive levels of prostaglandins, which are hormones that stimulate the uterus to contract during menstruation and childbirth, treatment must be tailored to individual patient symptoms. pharmacologic management with non-steroidal anti-inflammatory medications and/or combined hormonal contraceptives is most common. heat therapy, exercise, vitamins and dietary supplements have limited evidence and can be offered for patients seeking non-pharmacologic adjunctive or alternative options. greater awareness for both health-care providers and patients allow for early intervention to reduce impact on quality of life and life course potential. the significance of this study to assess the effect of virtual reality therapy on primary dysmenorrhea.

Eligibility criteria:
inclusion criteria: * age 17- 21 years old. * the body mass index (bmi) \< 30 kg/m2. * unmarried females. * females with dysmenorrhea pain. * females with regular menstrual cycles. * females with normal gynecology. exclusion criteria: * have a pathological disease related to reproduction. * students who use analgesic drugs for 3 months/3 menstrual cycles. * students with menstrual pain secondary to diagnosed organic or inflammatory causes.
retrospective registry of patients with acute heparin-induced thrombocytopenia type ii

Conditions: Acute HIT II (Heparin-induced Thrombocytopenia Type II)

Summary: the purpose of this retrospective registry is to collect data about patients with acute hit ii (heparin-induced thrombocytopenia type ii) which were treated with lepirudin, danaparoid, argatroban or fondaparinux. it is a main objective of this registry to mirror the daily routine in this indication in germany.


Eligibility criteria:
inclusion criteria: * acute hit ii (heparin-induced thrombocytopenia type ii), 4t-score * treatment of hit with lepirudin, danaparoid, argatroban or fondaparinux exclusion criteria: -

Keywords: retrospective evaluation of patients with acute heparin-induced thrombocytopenia type ii treated with fondaparinux
postoperative nudges to reduce opioid prescribing

Conditions: Opioid Prescribing

Summary: this study tests the effectiveness of two email-based behavioral nudges, one based on peer behavior and one based on best practice guidelines, in reducing excessive opioid prescriptions after surgery. it will be conducted in three surgical specialties (general surgery, orthopedic surgery, and obstetric/gynecological surgery) at 19 hospitals within one healthcare system. these specialties will each be randomized to a control group or one of two nudge groups. each month for one year, surgeons in the nudge groups will receive emails comparing their opioid prescribing either to their peers' prescribing or to prescribing guidelines. both types of email-based nudges are expected to reduce opioid prescribing after surgery.


Eligibility criteria:
the nudges that a surgeon in either intervention arm will receive are based on that surgeon's eligible discharge opioid prescriptions in the previous month. eligible prescriptions meet all of the following criteria: * the patient is at least 18 years old at the date of surgery * the patient is discharged to their home * the surgical procedure has an applicable post-operative opioid prescribing guideline * the surgical procedure is the only surgical procedure performed during the patient's hospital stay * the prescription is for an opioid taken orally (tablets, capsules, or liquid solution) to avoid contamination between the intervention arms, surgeons who operate across multiple surgical specialties (defined as surgeons who performed less than 90% of their total procedures in one specialty between june 2020 and may 2021) will not be eligible.

Keywords: opioid epidemic inappropriate prescribing opioid-related disorders practice guideline peer influence nudges
replenishing and maintaining vitamin d status in older adults in residential care facilities in ni

Conditions: Vitamin D Deficiency

Summary: the vitamin d status of older adults in residential care facilities in northern ireland (ni) is currently unknown. an observation study is currently being carried out by ulster university and the western health \& social care trust (whsct) to provide data on the prevalence of vitamin-d deficiency among older adults within residential care facilities in ni. it is expected that some 40% of the cohort will be deficient in vitamin d and will require immediate replenishment of vitamin d status. therefore, as a follow up to the observational study, an intervention study will be conducted, where participants identified as vitamin d deficient (25(oh)d) status \<30nmol/l (cut-off currently used by the whsct will be re-contacted and provided with a vitamin d supplement. the aim of this study is to investigate the dose and duration of vitamin d supplementation that is required to replenish and maintain vitamin d status in older adults with vitamin d deficiency within residential care facilities. participants will be randomly assigned to receive one of two supplementation regimes: 3200iu/day vitamin d3 or 20,000iu/week vitamin d3. blood samples (no more than 20ml per appointment) will be taken at 4 different time points: week 0, week 2, week 4 and week 8. these two doses are routinely used in clinical practice for remedial supplementation of vitamin d and have been chosen based upon their availability from manufacturers of vitamin d supplements. also, albeit these doses are currently routinely used to replenish vitamin d status little is known on how effective they are and how soon vitamin d status is optimised. clinicians can only administer medication for the management of osteoporosis (e.g. bisphosphonates) once vitamin d status is optimised. therefore, measurements will be taken every two weeks to establish response to the remedial supplementation. this project provides a unique opportunity to monitor the replenishment and maintenance of vitamin d status following remedial supplementation more regularly (at weeks 0,2,4,8) than would be done under standard national health service care. this does and duration of vitamin d required to replenish vitamin d deficiency in older adults is currently ambiguous within the literature and clinical care.


Eligibility criteria:
inclusion criteria: * currently residing (≥1 month) within residential care facilities in northern ireland and who have previously undertaken the observation study (full title: a cross-sectional analysis of vitamin d status and bone health of older adults within residential care facilities in northern ireland) and have been identified as vitamin d deficient. exclusion criteria: * participants will be excluded from the study if by the judgement of the consultant rheumatologist that they have very abnormal bone or vitamin d metabolism due to conditions such as end stage renal failure or bone metastases.

Keywords: vitamin d deficiency bone health generic health relevance musculoskeletal health intervention
tuberculosis diagnosis by flow cytometry

Conditions: Tuberculosis

Summary: tuberculosis and hiv continue to be major public health problems in resource constrained settings like zambia. zambia is among the top 30 highest burden countries globally. the major drivers of tb in the africa region is the hiv epidemic. inadequate tb diagnostic tools with failure to make a timely diagnosis and start appropriate treatment are the major impediments to tb control in zambia and globally.

project orion is focused on utilizing flow cytometry technology to screen and diagnose tuberculosis. there are two assays being tested under this project: 1. activated tb assay for differentiation of latent and active tb infection using blood samples and 2. direct tb assay (dta) for rapid detection and dst of mycobacterium tuberculosis (mtb) using sputum specimens.)

Eligibility criteria:
inclusion criteria: * presumptive tb patients (patients recommended for tuberculosis diagnostic testing and not on att) * patients with multi-drug resistant tb (mdr-tb) * paediatric patients (\< 15 years old) * patients suspected of extra-pulmonary tuberculosis * patients with tb/hiv co-infection exclusion criteria: * unable/unwilling to sign informed consent
high dose sequential therapy and autologous stem cell rescue for multiple myeloma

Conditions: Multiple Myeloma

Summary: to assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

to assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and vp-16 followed by total body irradiation or bcnu and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.

Eligibility criteria:
inclusion criteria:- received cytoreduction prior to transplant * adequate organ function exclusion criteria:- previous transplant * smoldering mm or benign monoclonal gammopathy
proton therapy for low and intermediate risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.

low risk - total of 70 gy/cge over 28 treatments intermediate risk - total of 72.5 gy/cge over 29 treatments

Eligibility criteria:
inclusion criteria * prostate cancer. * gleason score 2-7. * psa ≤ 20 ng/ml. exclusion criteria: * previous prostate cancer surgery or pelvic radiation. * prior or current chemotherapy for prostate cancer. * active inflammatory bowel disease (crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. * history of proximal urethral stricture requiring dilatation. * history of hip replacement. * diabetes requiring medication. * prior intrapelvic surgery. * current and continuing anticoagulation with warfarin sodium (coumadin), clopidogrel bisulfate (plavix), enoxaparin sodium (lovenox), or aspirin/er dipyridamole (aggrenox). * on flomax (tamsulosin), hytrin (terazosin) or cardura (doxazosin), uroxatral (alfuzosin hcl). * taking saw palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.

Keywords: prostate cancer proton radiation
improving diabetes by reconstruction methods in gastric cancer patients with diabetes mellitus

Conditions: Gastric Cancer; Diabetes

Summary: this study is to investigate the effect of gastrectomy on remission of type 2 diabetes in patients with gastric cancer and type 2 diabetes, to investigate the mechanism of blood glucose alteration and intestinal hormonal signaling by the reconstruction methods, and to evaluate the applicability and efficacy of roux-en-y gastrojejunostomy after gastrectomy in gastric cancer patients with diabetes.

purpose: * to investigate the effect of gastrectomy on remission of type 2 diabetes in patients with gastric cancer and type 2 diabetes * to investigate the mechanism of blood glucose alteration and intestinal hormonal signaling by the reconstruction methods * to evaluate the applicability and efficacy of roux-en-y gastrojejunostomy after gastrectomy in gastric cancer patients with diabetes contents: * evaluation of the status of diabetes in gastric cancer patients with dm after gastrectomy * comparison of two reconstruction types after gastrectomy bypass duodenum and upper jejunum: roux-en-y gastrojejunostomy preservation of duodenal passage: gastroduodenostomy * analysis for biochemical markers reflecting diabetic status: fasting glucose, postprandial 2h glucose, hba1c, c-peptide, lipid profile * correlation of parameters associated with diabetes and gi hormones * measurement of gi hormones which have an effect on glucose tolerance * insulin, glucagon, igf-1, glp-1, neuropeptide y, ghrelin, leptin * correlation of reconstruction methods, parameters of diabetes and gi hormone levels * evaluation of mechanism of roux-en-y gastrojejunostomy on controlling diabetes * evaluation of feasibility of roux-en-y gastrojejunostomy in gastric cancer surgery in patients with dm * degree of high blood glucose control, the amount of antidiabetic medication, costs for dm treatment, quality of life assessment * analysis for the mechanism of gastrointestinal physiology to diabetes control

Eligibility criteria:
inclusion criteria: * patient who are older than 20 years and younger than 80 years * histologically confirmed gastric adenocarcinoma located lower one third of stomach * postoperative confirmed pt1n0, pt2n0, pt1n1 * informed consent exclusion criteria: * previous history of treatment for other malignancy or inflammatory disease * preoperative uncontrolled serious comorbidity * vulnerable subjects(pregnant women, children, cognitively impaired persons etc.) * patient who experience any complications requiring reoperation following gastrectomy

Keywords: early gastric cancer
therapeutic effect and safety of combined hydroxyurea with recombinant human erythropoietin.

Conditions: Thalassemia Intermedia

Summary: the study hypothesis that treatment with erythropoietin (epo) combined with human erythropoietin (huo) therapy will result in hematologic improvement in thalassemia intermedia patients. second is to determine whether any of the following correlate with improved hematologic response: a decrease in hemolysis, as assayed by a decrease in ldh, compared to baseline levels,baseline erythropoietin levels,baseline hemoglobin levels and baseline reticulocyte counts (or % circulating nucleated erythroblasts/100 wbcs). goal: the aim is to assess the possibility of steady increase of hemoglobin levels in thalassemia intermedia patients by at least 1g/dl above baseline levels during therapy using hydroxyurea and erythropoietin, growth evaluation,quality of life (qol) and decline transfusion requirements during study period. also to report and compare adverse events with other published data regarding.

to determine whether any of the following correlate with improved hematologic response: a decrease in hemolysis, as assayed by a decrease in ldh, compared to baseline levels,baseline erythropoietin levels,baseline hemoglobin level and baseline reticulocyte counts (or % circulating nucleated erythroblasts/100 wbcs). to assess the possibility of steady increase of hemoglobin levels in thalassemia intermedia patients by at least 1g/dl above baseline levels during therapy using hydroxyurea and erythropoietin, growth evaluation , quality of life ( qol ) and decline transfusion requirements during study period. also to report and compare adverse events with other published data regarding. the following criteria are used when including the patient in the study: patients with thalassemia intermedia.diagnosis based on genetic mutations, hemoglobin electrophoresis and characteristic clinical data at presentation. patients requiring different transfusion requirements and not transfusion dependent.patients having a baseline hemoglobin of less than or equal to 6-8g/dl.patients with normal renal and liver function.

Eligibility criteria:
inclusion criteria: * patients with thalassemia intermedia. diagnosis based on genetic mutations, hemoglobin electrophoresis and characteristic clinical data at presentation. * require different transfusion requirements and not transfusion dependent. * have a baseline hemoglobin of less than or equal to 6-8g/dl. * patients with normal renal and liver function. exclusion criteria: * evidence of active hepatitis (alt \> 5 times above uln). * evidence of renal impairment (serum creatinine \> uln). * patients who are dependent on red blood cell transfusions.

Keywords: hydroxyurea erythropoitin therapy thalassemia intermedia
geko venous leg ulcer study

Conditions: Venous Leg Ulcer

Summary: this study is designed to look at the effect of the geko device on the circulation in lower limbs of participants with venous leg ulcers.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. intact healthy skin at the site of device application 3. able to understand the patient information sheet 4. willing to give informed consent 5. willing to follow the requirements of the protocol 6. subjects who had a chronic venous leg ulcer (i.e. ceap classification of c6 1) greater than 2 cm2 and less than 10 cm in maximum diameter, 7. abpi of 0.8 or greater exclusion criteria: 1. history of significant haematological disorders or dvt with the preceding six months 2. pregnant 3. pacemakers or implantable defibrillators 4. use of any other neuro-modulation device 5. current use of tens in pelvic region, back or legs 6. use of investigational drug or device within the past 4 weeks that may interfere with this study 7. recent surgery (such as abdominal, gynaecological, hip or knee replacement) 8. recent trauma to the lower limbs 9. size of leg incompatible with the geko™ device. 10. chronic obesity (bmi \> 34) 11. any medication deemed to be significant by the investigator 12. subjects who had an index venous leg ulcer greater in maximum diameter than 10cm in any one dimension 13. diabetic subjects with advanced small vessel disease
primary prophylaxis of hepatic encephalopathy in patients with cirrhosis

Conditions: Hepatic Encephalopathy

Summary: to assess the effects of lactulose for the prevention of first episode of altered sensorium (hepatic encephalopathy, primary prophylaxis) in patients with cirrhosis.

development of hepatic encephalopathy in a patient with cirrhosis is associated with poor survival rate of 10-70% at one year depending upon hepatic and renal functions. treating patients to prevent development of first episode of hepatic encephalopathy is classified as primary prophylaxis of hepatic encephalopathy and preventing recurrence of hepatic encephalopathy in patients who had previous episode of hepatic encephalopathy is secondary prophylaxis of hepatic encephalopathy

Eligibility criteria:
inclusion criteria: * cirrhotic patients(18-70yrs) who never had encephalopathy exclusion criteria: * history of taking lactulose in the past 6 weeks * alcohol intake during the past 6 weeks * hepatocellular carcinoma * previous tips or shunt surgery * significant co morbid illness such as heart, respiratory, or renal failure * neurologic diseases such as alzheimer's disease, parkinson's disease and nonhepatic metabolic encephalopathies. * patients on psychoactive drugs such as antidepressants or sedatives * who restarted alcohol during follow up

Keywords: hepatic encephalopathy lactulose
use of biperiden for the prevention of post-traumatic epilepsy

Conditions: Traumatic Brain Injury

Summary: there is no aed or medication that has been demonstrated to affect the development of post-traumatic epilepsy. biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti parkinson drug. the investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.

treatment with biperiden should be initiated in the first 12 hours after trauma as means to avoid the epileptogenic process. the treatment will be repeated every 6 hours for 10 consecutive days. the efficacy of biperiden as an antiepileptogenic drug will be established by analyzing the development of pte between the biperiden and placebo groups. several patients' aspects (clinical, electroencephalography, brain imaging, genetic and behavioral data) will be monitored for two year follow-up to unravel the mechanisms by which biperiden exerts its actions on epileptogenesis. the investigators are already at the early stages of patient's recruitment using the available resources.

Eligibility criteria:
inclusion criteria: * between 18 and 75 year of age * patients with a diagnosis of acute tbi admitted to an emergency unit within 12 hours of the accident, regardless of the accident * brain ct scan with signs of acute intraparenchymatous contusion * signed informed consent (possibly by a relative) exclusion criteria: * malignant neoplasia and other severe comorbidities * neurodegenerative disorders * previous cerebrovascular accident * record of convulsive seizures or use of anti-epileptic medication * pregnancy * concomitant use of the other anticholinergic medications * presence of any factor that may contraindicate the use of biperiden * participation in other clinical trial * alcohol intoxication will not lead to exclusion of the subject.

Keywords: biperiden post-traumatic epilepsy traumatic brain injury
evaluation of hpgd and sclo2a1 expression in clear cell renal cell carcinoma patients

Conditions: Clear Cell Renal Cell Carcinoma (ccRCC)

Summary: this study aims to investigate the role of hpgd in clear cell renal cell carcinoma (ccrcc). specifically, it will focus on hpgd's impact on proliferation, epithelial-mesenchymal transition (emt), and prognosis. the study will analyze gene expression data from clinical samples and use techniques like rt-qpcr, western blotting, and immunohistochemistry to assess hpgd expression levels. additionally, the research will explore the relationship between hpgd and patient survival outcomes. by elucidating hpgd's contribution to cancer progression, the study seeks to identify potential therapeutic targets for improving renal cancer treatment.

this study is designed to comprehensively explore the role of 15-hydroxyprostaglandin dehydrogenase ( hpgd) in clear cell renal cell carcinoma development and progression. hpgd has been implicated in various cancers, with evidence suggesting its involvement in tumorigenesis, emt, and poor prognosis. however, its specific function n clear cell renal cell carcinoma (ccrcc) is still unclear. this research will analyze clinical samples, including tumor tissues and normal adjacent tissues, to evaluate hpgd expression through a combination of advanced laboratory techniques such as quantitative real-time pcr (qrt-pcr), western blotting, immunohistochemistry (ihc) and rna sequencing. furthermore, hpgd-interacting proteins were predicted using string and tcga data, followed by pcr, western blot validation, and ihc. mechanistically, hpgd positively correlated with the solute carrier organic anion transporter 2a1 (slco2a1), and slco2a1 knockdown partially attenuated the tumor-suppressive effects of hpgd overexpression.. this study underscores the tumor-suppressive role of hpgd in ccrcc, highlighting its capacity to hinder cell proliferation and emt via its interaction with slco2a1. targeting the hpgd-slco2a1 axis may offer a promising novel therapeutic approach for ccrcc management.

Eligibility criteria:
inclusion criteria: adults aged 18 years or older. histologically confirmed diagnosis of clear cell renal cell carcinoma . measurable disease as per recist criteria. adequate organ function as defined by laboratory tests (e.g., liver, kidney, and hematologic function). hpgd expression level determined via biopsy or previous analysis. written informed consent provided. exclusion criteria: history of other malignancies within the past 5 years, excluding non-melanoma skin cancer or in situ carcinoma. prior treatment with hpgd inhibitors or similar targeted therapies. active or uncontrolled infections. pregnant or breastfeeding women. known autoimmune disorders or conditions requiring immunosuppressive therapy. inability to comply with the study protocol or procedures.

Keywords: hpgd clear cell renal cell carcinoma biomarker prognosis emt tumorigenesis slco2a1